We caught up with Jae H. Kim, MD, PhD, associate clinical professor of pediatrics, University of California, San Diego, via a Google Hangout, for key takeaways from his neonatal presentation at AAP 2013 in Orlando.
FDA extends approval of Evkeeza for homozygous familial hypercholesterolemia in young children
March 22nd 2023Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor indicated for patients as young at 5 years to control high levels of low-density lipoprotein cholesterol (LDL-C) as a result of HoFH.
2 Clarke Drive
Cranbury, NJ 08512